KODIKA Trademark

Trademark Overview

On Wednesday, December 23, 2020, a trademark application was filed for KODIKA with the United States Patent and Trademark Office. The USPTO has given the KODIKA trademark a serial number of 90406095. The federal status of this trademark filing is FIFTH EXTENSION - GRANTED as of Friday, October 4, 2024. This trademark is owned by Kodika Corporation. The KODIKA trademark is filed in the Pharmaceutical Products category with the following description:

pharmaceutical preparations for the treatment of oncology, neurodegenerative diseases and disorders, and inflammatory conditions
kodika

General Information

Serial Number90406095
Word MarkKODIKA
Filing DateWednesday, December 23, 2020
Status734 - FIFTH EXTENSION - GRANTED
Status DateFriday, October 4, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, February 8, 2022

Trademark Statements

Goods and Servicespharmaceutical preparations for the treatment of oncology, neurodegenerative diseases and disorders, and inflammatory conditions

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, March 10, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameKodika Corporation
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressCambridge, MA 02138
Party NameKodika Corporation
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCambridge, MA 02138

Trademark Events

Event DateEvent Description
Monday, June 21, 2021ASSIGNED TO EXAMINER
Saturday, December 26, 2020NEW APPLICATION ENTERED
Wednesday, March 10, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, June 22, 2021NON-FINAL ACTION WRITTEN
Tuesday, June 22, 2021NON-FINAL ACTION E-MAILED
Tuesday, June 22, 2021NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, December 22, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, December 22, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, December 22, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, January 5, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, January 19, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, February 8, 2022PUBLISHED FOR OPPOSITION
Tuesday, February 8, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, April 5, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, October 5, 2022SOU EXTENSION 1 GRANTED
Wednesday, October 5, 2022SOU TEAS EXTENSION RECEIVED
Wednesday, October 5, 2022SOU EXTENSION 1 FILED
Friday, March 31, 2023SOU EXTENSION 2 GRANTED
Friday, October 7, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, March 31, 2023SOU TEAS EXTENSION RECEIVED
Friday, March 31, 2023SOU EXTENSION 2 FILED
Tuesday, April 4, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, October 6, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, October 4, 2023SOU TEAS EXTENSION RECEIVED
Wednesday, October 4, 2023SOU EXTENSION 3 FILED
Wednesday, October 4, 2023SOU EXTENSION 3 GRANTED
Friday, April 5, 2024SOU TEAS EXTENSION RECEIVED
Friday, April 5, 2024SOU EXTENSION 4 FILED
Friday, April 5, 2024SOU EXTENSION 4 GRANTED
Friday, October 4, 2024SOU TEAS EXTENSION RECEIVED
Friday, October 4, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, October 4, 2024SOU EXTENSION 5 GRANTED
Friday, October 4, 2024SOU EXTENSION 5 FILED
Saturday, April 6, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

Related Keywords

kodika disorders inflammatory conditions diseases neurodegenerative preparations treatment oncology pharmaceutical